Core Viewpoint - Supernus Pharmaceuticals (SUPN) has consistently exceeded earnings estimates and is well-positioned for future earnings growth, particularly with its upcoming quarterly report expected on November 4, 2025 [1][8]. Earnings Performance - In the last reported quarter, Supernus achieved earnings of $0.91 per share, significantly surpassing the Zacks Consensus Estimate of $0.47 per share, resulting in a surprise of 93.62% [2]. - For the previous quarter, the company reported earnings of $0.42 per share against an expectation of $0.38 per share, delivering a surprise of 10.53% [2]. Earnings Estimates and Predictions - Recent estimates for Supernus have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) of +11.86%, indicating growing analyst optimism regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) suggests a high likelihood of another earnings beat in the upcoming report [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].

[Form 8-K Filing Details](index=1&type=section&id=Form%208-K%20Filing%20Details) This section provides the foundational details of the Form 8-K filing, including registrant identification and filing specifics [Registrant Information](index=1&type=section&id=Registrant%20Information) This section provides the core identification details for Supernus Pharmaceuticals, Inc. as the registrant, including its incorporation state, commission file number, principal executive offices, and securities registered on Nasdaq - Registrant: **Supernus Pharmaceuticals, Inc.**[2](index=2&type=chunk) Registrant Details | Detail | Value | | :--- | :--- | | State of Incorporation | Delaware | | Commission File Number | 001-35518 | | I.R.S. Employer Identification No. | 20-2590184 | | Principal Executive Offices | 9715 Key West Ave, Rockville MD 20850 | | Registrant's Telephone Number | (301) 838-2500 | Registered Securities | Title of Class | Trading Symbol | Exchange | | :--- | :--- | :--- | | Common Stock, $0.001 par value per share | SUPN | The Nasdaq Stock Market LLC | [Filing Specifics](index=1&type=section&id=Filing%20Specifics) The report confirms the filing date and indicates that Supernus Pharmaceuticals, Inc. is not an emerging growth company - Date of Report (Date of earliest event reported): **October 21, 2025**[2](index=2&type=chunk) - The registrant is not an emerging growth company[3](index=3&type=chunk) [Current Report Items](index=2&type=section&id=Current%20Report%20Items) This section details the specific events reported in the Form 8-K, covering financial results and required exhibits [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Supernus Pharmaceuticals, Inc. announced its plan to release third-quarter 2025 business results and host a conference call and webcast on November 4, 2025, to discuss these financial and business outcomes - Supernus Pharmaceuticals, Inc. expects to report its **Q3 2025 business results** after market close on **Tuesday, November 4, 2025**[4](index=4&type=chunk) - A conference call and webcast will be held on **Tuesday, November 4, 2025, at 4:30 p.m. E.T.** to discuss the results[4](index=4&type=chunk) - A press release dated **October 21, 2025**, is furnished as **Exhibit 99.1**[4](index=4&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits filed with the Form 8-K, including the press release regarding Q3 2025 results and the Inline XBRL formatted cover page Exhibits Filed | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press Release dated October 21, 2025 filed as an Exhibit pursuant to Item 2.02 hereof | | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | [Signatures](index=3&type=section&id=Signatures) This section confirms the official authorization and signatory details for the Form 8-K filing [Authorization and Signatory](index=3&type=section&id=Authorization%20and%20Signatory) The report was duly signed on behalf of Supernus Pharmaceuticals, Inc. by Timothy C. Dec, Senior Vice President and Chief Financial Officer, on October 21, 2025 - Report signed on behalf of **Supernus Pharmaceuticals, Inc.**[9](index=9&type=chunk) - Signatory: **Timothy C. Dec**, Senior Vice President and Chief Financial Officer[10](index=10&type=chunk) - Date of Signature: **October 21, 2025**[10](index=10&type=chunk)

Core Insights - Supernus Pharmaceuticals, Inc. is set to announce its third quarter 2025 financial and business results on November 4, 2025, after market close [1] - A conference call will be hosted by the President and CEO, Jack Khattar, and Senior Vice President and CFO, Tim Dec, on the same day at 4:30 p.m. ET to discuss the results [2] - The call will be accessible via a live webcast on the Company's Investor Relations website, with a replay available for 60 days post-call [3] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system (CNS) diseases [4] - The company's neuroscience portfolio includes treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5]

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Style Analysis - Momentum investing focuses on following a stock's recent price trends, with the aim of capitalizing on established price movements [1]. - The Zacks Momentum Style Score helps investors identify stocks with strong momentum characteristics, addressing the challenges of defining momentum [2]. Performance Metrics - Over the past week, SUPN shares increased by 2.81%, matching the performance of the Zacks Medical - Generic Drugs industry [6]. - In a longer timeframe, SUPN's monthly price change is 7.79%, significantly outperforming the industry's 0.5% [6]. - Over the past quarter, SUPN shares have surged by 51.51%, and over the last year, they have gained 48.49%, while the S&P 500 only increased by 4.67% and 14.71%, respectively [7]. Trading Volume - SUPN's average 20-day trading volume is 808,093 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - Recent earnings estimate revisions for SUPN show one upward revision for the full year, increasing the consensus estimate from $2.05 to $2.25 over the past 60 days [10]. - For the next fiscal year, there has been one upward revision with no downward revisions noted [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, SUPN is positioned as a promising investment opportunity in the near term [12].

Core Viewpoint - Supernus Pharmaceuticals has shown strong stock performance, with a 36.9% increase year-to-date, significantly outperforming the Zacks Medical sector and the Zacks Medical - Generic Drugs industry [1][2]. Financial Performance - Supernus has consistently exceeded earnings expectations, reporting an EPS of $0.91 against a consensus estimate of $0.47 in its last earnings report [2]. - For the current fiscal year, Supernus is projected to achieve earnings of $2.24 per share on revenues of $696.95 million, reflecting a -28.34% change in EPS and a 5.31% change in revenues. The next fiscal year is expected to see earnings of $2.31 per share on revenues of $843.62 million, indicating a year-over-year change of 2.89% in EPS and 21.05% in revenues [3]. Valuation Metrics - Supernus currently trades at 22.1 times the current fiscal year EPS estimates, which is a premium compared to the peer industry average of 8.2 times. On a trailing cash flow basis, it trades at 11.9 times versus the peer group's average of 5.7 times [6]. Style Scores and Zacks Rank - Supernus has a Value Score of C, a Growth Score of C, and a Momentum Score of A, resulting in a VGM Score of B. The Zacks Rank for Supernus is 1 (Strong Buy), supported by favorable earnings estimate revisions from analysts [5][7].

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Zacks Rank of 1 (Strong Buy) and a Momentum Style Score of B, indicating potential for significant near-term gains [4][12]. Company Performance - SUPN shares have increased by 1.28% over the past week, outperforming the Zacks Medical - Generic Drugs industry, which rose by 0.97% during the same period [6]. - Over the last month, SUPN's stock price has risen by 4.5%, compared to the industry's 1.4% [6]. - In the last quarter, SUPN shares have surged by 46.87%, and over the past year, they have gained 57.31%, significantly outperforming the S&P 500, which increased by 9.31% and 17.01% respectively [7]. Trading Volume - The average 20-day trading volume for SUPN is 645,479 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for SUPN have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $1.50 to $2.18 [10]. - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10].

Core Viewpoint - Supernus Pharmaceuticals has shown strong stock performance, with a 5.7% increase over the past month and a 29.9% rise since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Generic Drugs industry [1][2]. Financial Performance - Supernus has consistently exceeded earnings expectations, reporting an EPS of $0.91 against a consensus estimate of $0.47 in its last earnings report [2]. - For the current fiscal year, Supernus is projected to achieve earnings of $2.18 per share on revenues of $696.95 million, reflecting a -30.57% change in EPS and a 5.31% change in revenues. For the next fiscal year, earnings are expected to rise to $2.31 per share on revenues of $843.62 million, indicating a year-over-year change of 5.96% and 21.05%, respectively [3]. Valuation Metrics - Supernus has a Value Score of B, with Growth and Momentum Scores of C, resulting in a combined VGM Score of B. The stock trades at 21.6 times current fiscal year EPS estimates, which is a premium compared to the peer industry average of 8.5 times [5][6]. - On a trailing cash flow basis, Supernus trades at 11.3 times, while the peer group's average is 5.6 times, suggesting that the company is not positioned in the top tier from a value perspective [6]. Zacks Rank - Supernus holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, aligning with the recommendation for investors to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, indicating potential for further stock price appreciation [7].

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Bret leads the investing group The Biotech Forum , in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group ...

Group 1 - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat for trade discussions and weekly research updates [2] - The forum includes frequent discussions on specific covered call trades, providing insights into current trading strategies [1] - The group provides market commentary and portfolio updates every weekend, enhancing investor engagement and information flow [2] Group 2 - Analysts involved in the forum may hold beneficial long positions in stocks discussed, indicating a vested interest in the performance of these investments [3] - The forum operates independently, with analysts expressing personal opinions and not receiving compensation from companies mentioned [3][4] - Seeking Alpha emphasizes that past performance does not guarantee future results, highlighting the importance of independent research for investors [4]

Financial Data and Key Metrics Changes - The company continues to be profitable even through the transition from legacy products to new growth products [4] - KELBRE has shown a 25% growth in prescriptions year-over-year and a 23% growth in the first half of the current year [16] - GOCOVRI has seen a significant increase in patient retention due to Medicare redesign, with 97% of patients having less than $25 co-pay by June [24] Business Line Data and Key Metrics Changes - KELBRE has grown to 35% of the business, with an 80% satisfaction rate among adult users, significantly higher than Strattera's 53% [13] - ZERZUVEY, the first oral treatment for postpartum depression, is expected to set the standard of care, with 80% of women receiving it as a first-line treatment [7] - Anapco, the new infusion device for Parkinson's, is performing well, with demand matching that of AbbVie's product [30] Market Data and Key Metrics Changes - The back-to-school season has shown a 26% growth in the last four-week rolling average for KELBRE, indicating strong momentum [17] - The company has seen a 36% growth in unit shipments of ZERZUVEY quarter-over-quarter, reflecting a healthy brand performance [36] Company Strategy and Development Direction - The acquisition of Sage allows the company to enter women's health while maintaining its CNS focus, indicating a strategic expansion [5] - The company is prioritizing M&A to fill its portfolio with post-Phase II assets, aiming for launches between 2026 and 2030 [58][59] - The company is taking a pause to reevaluate the Sage pipeline while integrating it with its own discovery programs [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of ZERZUVEY to become the standard of care for postpartum depression [8] - The company anticipates a strong second half of the year, driven by back-to-school momentum and continued growth in its product portfolio [19] - Management is confident that the increased demand from Medicare redesign will offset the mandatory rebates on manufacturers [26] Other Important Information - The company is exploring the potential of its pipeline, particularly focusing on SPN-817 for seizures, which has shown promising results [41] - The company is also considering the future of XERZUVEY and its potential new indications in collaboration with Biogen [39] Q&A Session Summary Question: Can you discuss the acquisition rationale for Sage? - The acquisition allows entry into women's health while maintaining CNS focus, addressing a significant unmet need in postpartum depression [5] Question: What are the expectations for the collaboration with Biogen? - The collaboration is expected to be mutually beneficial, with both companies learning from each other across various functions [10] Question: How is KELBRE performing in the adult ADHD market? - KELBRE has achieved 35% of the business in adults, with an 80% satisfaction rate, indicating strong market acceptance [13] Question: What is the outlook for GOCOVRI following Medicare redesign? - The redesign has improved patient retention, with 97% of patients having low co-pays, which is expected to continue [24] Question: How is Anapco performing compared to AbbVie's product? - Anapco's performance is in line with AbbVie's product, with both addressing a significant need in the market for advanced Parkinson's treatment [30] Question: What is the company's approach to M&A? - The company remains focused on acquiring post-Phase II assets to enhance its portfolio and ensure future growth [58][59]